Co-Authors
This is a "connection" page, showing publications co-authored by JAMES C YAO and RUSSELL BROADDUS.
Connection Strength
0.161
-
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
Score: 0.045
-
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
Score: 0.037
-
Expression of estrogen-induced genes and estrogen receptor ? in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas. 2014 Oct; 43(7):996-1002.
Score: 0.031
-
Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36.
Score: 0.031
-
Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005 Dec; 18(12):1632-40.
Score: 0.017